The global PEGylated proteins market was surpassed at USD 12,786 million in 2021 and is expected to hit around USD 22,967 million by 2030, growing at a CAGR of 7.2% from 2022 to 2030.
The global PEGylated proteins market was surpassed at USD 12,786 million in 2021 and is expected to hit around USD 22,967 million by 2030, growing at a CAGR of 7.2% from 2022 to 2030.
PEGylation is the process of a combination of polyethylene glycol (both covalent and non-covalent) polymer chains with molecules, proteins, and peptides. This is useful in targeted drug delivery systems and in genetically modifying cells. These molecules have a long half-life (in the bloodstream), reduced toxicity, decreased immunogenicity, and increased proteolytic protection. Separation of the PEGylated proteins is done using chromatography. It includes such as size exclusion chromatography (SEC), hydrophobic interaction chromatography, and electrostatic interaction chromatography (ion-exchange chromatography, IEC). On the other hand, the process cost of the process is comparatively high. Polyethylene glycol is regarded as safe by US FDA for internal administration.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39705
PEGylation of proteins also has pharmacological advantages and significance which include improved drug solubility, reduced dosage frequency, increased drug stability, and minimum loss of biological activity. Some of FDA approved pegylated drugs are Cimzia, Mircera, Macugen, Somavert, Pegasys, and Neulasta. These drugs are useful to treat various diseases like Crohn’s disease, anemia in chronic kidney disease, age-related macular degeneration, Acromegaly, hepatitis C, and Neutropenia during chemotherapy. PEG molecules in the conjugation of nanoparticles are used in the advanced drug-delivery systems for anti-cancer therapy.
The research on PEGylated protein drugs focuses on adenosine deaminase, asparaginase, interferons, granulocyte colony-stimulating factor, interleukins, etc. Recently JenKem Technology is the large-scale manufacturer of PEG derivatives of lipid nanoparticles and other intermediates. Increased incidence of cancer and delay in the diagnosis is been observed all over the globe as per the research of JCO Clinical Cancer Informatics in the U.S. The awareness among the patients and healthcare professionals is observed for the adverse effects of cancer treatments like chemotherapy. So the major focus for alternative therapeutics treatment like pegylated peptide-based drugs, colony-stimulating factors is the driving factor for the growth of the market in the forecast years.
The PEGylated protein market is segmented based on product type, protein type, application, end-user, and region. On the basis of product type the market is segmented into consumables and services. Consumables include PEGylation kits and PEGylation reagents. Based on the protein type, the market is segmented based on colony-stimulating factor, interferons, erythropoietin, and recombinant factor VII.
North America dominates the markets due to the rise in the prevalence of chronic diseases like cancer. The cancer treatment estimates the highest CAGR during the forecast period. This is due to the increase in the adoption of new drugs for the treatments like monoclonal antibodies, interferons, and many more. Along with this the increase in government funding, and grants for research projects with the advancements in the field of biotechnology and research and development boost the North American PEGylated Protein Market.
Scope of The Report
|
Report Coverage |
Details |
|
Market Size in 2021 |
USD 12,786 million |
|
Revenue Forecast by 2030 |
USD 22,967 million |
|
Growth rate from 2022 to 2030 |
CAGR of 7.2% |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segmentation |
Type, Protein, Application, End user, Region |
|
Companies Covered |
Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., UCB S.A, AstraZeneca, Amgen, Inc., Biogen, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Coherus Biosciences, Biomarin Pharmaceutical Inc., Enzon, Leadient Biosciences, Inc. |
Key Market Trends
The Colony-stimulating Factors Segment is Expected to Grow at the Highest Rate in the Forecast Period
Colony-stimulating factors are substances that accelerate the production of blood cells and elevate their ability to function. They do not directly influence tumors but have a role in stimulating blood cells, and hence, these factors can be beneficial in supporting a person's immune system during cancer treatment.
According to the research article published in the JCO Clinical Cancer Informatics, 2020, COVD-19 has resulted in the delay in the diagnosis of new cancer cases and also in the delivery of on-time treatment of cancer patients in the United States. Hence, the COVID-19 pandemic is expected to impact the studied segment due to the decrease in cancer care globally.
The market growth of the segment is due to the increasing incidence of cancer across the globe, and the usage of peptide treatment for cancer. According to Globocan 2020, the incidence of cancer cases in 2020 was estimated to be 19,292,789 cases worldwide, with nearly 9,958,133 deaths due to cancer in 2020. Additionally, the five-year prevalent cases were estimated as 50,550287 cancer cases by 2020, with a 201.0 age-standardized incidence rate globally. Thus, the high incidence of cancer surges the need for colony-stimulating factors in its effective treatment and thus drives the segment growth.
Furthermore, the expanded awareness among patients and healthcare professionals regarding the adverse effects of other methods of cancer treatments, such as chemotherapy and radiation therapy, is a major factor for the growing focus toward alternative therapeutics such as pegylated peptide-based drugs. Hence, the aforementioned factors are expected to positively drive the growth of the colony-stimulating factors segment over the forecast period.
Key Players
- Thermo Fisher Scientific Inc.
- Horizon Therapeutics Plc.
- Novo Nordisk A/S
- F. Hoffmann-La Roche Ltd.
- UCB S.A
- AstraZeneca
- Amgen, Inc.
- Biogen
- Merck & Co. Inc.
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Coherus Biosciences
- Biomarin Pharmaceutical Inc.
- Enzon
- Leadient Biosciences, Inc.
Market Segmentation
- By Type
- By Protein
- By Application
- By End user
- By Region
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39705
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/